Macroautophagy Dysfunction in PD - Experiment Design

Migration, Crosslink

📖

Macroautophagy Dysfunction in PD - Experiment Design

active

wiki page Created: 2026-04-02T07:20:09 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-experiments-macroautophagy-dysfunct

📖 Wiki Page

experiment926 wordssynced 2026-04-02

Macroautophagy Dysfunction Validation in PD - Experiment Design

Experiment Overview

Study Code: MA-PD-001 Hypothesis: Macroautophagy dysfunction is an upstream driver of alpha-synuclein aggregation in Parkinson's Disease Phase: Preclinical + Clinical Translation

Pathway / Mechanism Diagram

graph TD A["Nutrient Deprivation / Stress"] --> B["AMPK Activation"] B --> C["ULK1 Complex Activation"] A --> D["mTORC1 Inhibition"] D --> C C --> E["Phagophore Nucleation (VPS34/Beclin-1)"] E --> F["LC3 Lipidation (LC3-II)"] F --> G["Autophagosome Formation"] G --> H["Cargo Recognition (p62/SQSTM1)"] H --> I["Autophagosome-Lysosome Fusion"] I --> J["Cargo Degradation"] J --> K["Amino Acid Recycling"] K --> L["Cell Survival"] M["Autophagy Impairment in Aging"] --> N["Aggregate Accumulation"] N --> O["Tau, Abeta, alpha-Synuclein Buildup"] O --> P["Neurodegeneration"] style L fill:#1b5e20,color:#e0e0e0 style P fill:#ef5350,color:#e0e0e0 style G fill:#006494,color:#e0e0e0

Study Design

Phase 1: Basic Research (In vitro)

1.1 Autophagic Flux in PD Patient Neurons

Objective: Validate impaired macroautophagy in dopaminergic neurons from PD patients

Models:

iPSC-derived dopaminergic neurons from:
PD patients with ATG5 mutations (n=3)
PD patients with idiopathic PD (n=3)
Healthy controls (n=3)

...

Macroautophagy Dysfunction Validation in PD - Experiment Design

Experiment Overview

Study Code: MA-PD-001 Hypothesis: Macroautophagy dysfunction is an upstream driver of alpha-synuclein aggregation in Parkinson's Disease Phase: Preclinical + Clinical Translation

Pathway / Mechanism Diagram

Mermaid diagram (expand to render)

Study Design

Phase 1: Basic Research (In vitro)

1.1 Autophagic Flux in PD Patient Neurons

Objective: Validate impaired macroautophagy in dopaminergic neurons from PD patients

Models:

iPSC-derived dopaminergic neurons from:
PD patients with ATG5 mutations (n=3)
PD patients with idiopathic PD (n=3)
Healthy controls (n=3)

Endpoints:

LC3-II/LC3-I ratio (Western blot) - baseline and after chloroquine treatment
p62 turnover (Western blot) - to measure autophagic flux
mTORC1 activity (p-S6K, p-4E-BP1)
ULK1 phosphorylation at Ser757 (mTORC1 inhibition site)

1.2 mTORC1 Inhibition Effect on α-synuclein

Objective: Determine if mTORC1 hyperactivation promotes α-synuclein accumulation

Models:

SH-SY5Y cells expressing wild-type or mutant α-syn (A53T, A30P)
mTORC1 activator (MHY1485) vs. inhibitor (rapamycin) treatment

Endpoints:

α-synuclein levels (total and oligomeric)
LC3-II formation (autophagosome number)
p62 degradation (autophagic flux)
Cell viability (MTT, caspase 3/7)

1.3 ATG5/ATG7 Knockout Effect

Objective: Test if ATG5/ATG7 deficiency recapitulates PD pathology

Models:

CRISPR/Cas9 knockout of ATG5 or ATG7 in SH-SY5Y cells
α-syn (WT/A53T) overexpression in knockout cells

Endpoints:

Autophagosome formation (LC3 puncta counting)
α-syn aggregation (Thioflavin S, α-syn PSer129)
Mitochondrial function (JC-1, ATP assay)
Cell death markers

Phase 2: Preclinical (In vivo)

2.1 Rapamycin in α-syn transgenic mice

Objective: Test mTOR inhibition and autophagy enhancement in vivo

Models:

Thy1-α-syn transgenic mice (line M83)
Treatment: Rapamycin (10 mg/kg, i.p., daily) vs. vehicle

Treatment:

6-month-old mice (pre-symptomatic)
3-month treatment duration
6-month-old mice (symptomatic) for rescue study

Endpoints:

Motor behavior (rotarod, pole test, cylinder test, gait analysis)
α-syn pathology (pSer129, oligomers, load)
Autophagy markers (LC3-II, p62) in substantia nigra
Dopaminergic neuron survival (TH+ count)
Mitochondrial function (complex I activity)

2.2 ATG5 Overexpression in vivo

Objective: Test if ATG5 restoration protects against neurodegeneration

Models:

Atg5 conditional knockout mice (Nestin-Cre; Atg5f/f)
AAV9-ATG5 vs. AAV9-GFP injection

Endpoints:

Autophagosome formation in neurons
α-syn pathology progression
Motor behavior
Neuronal survival

2.3 Autophagy inducer compound screening

Objective: Identify small molecules that enhance macroautophagy independent of mTOR

Primary Screen:

FDA-approved library (2800 compounds)
Secondary: Natural product library (500 compounds)

Assay:

LC3-II formation in SH-SY5Y cells
p62 turnover
Cytotoxicity counter-screen

Hits:

mTOR-independent activators (e.g., carbamazepine, trehalose, lithium)
Validation in patient-derived neurons

Phase 3: Clinical Translation

3.1 Biomarker Validation Study

Objective: Validate macroautophagy biomarkers in PD patients

Cohort:

Early-stage PD (n=100, H&Y 1-2)
Prodromal PD (n=50, REM sleep behavior disorder)
Healthy controls (n=100)

Biomarkers:

Peripheral blood mononuclear cell (PBMC) LC3-II/LC3-I ratio
p62 levels in PBMCs
CSF autophagic markers (LC3, p62)
mTORC1 activity (p-S6K in lymphocytes)

Correlations:

Disease severity (MDS-UPDRS)
Progression rate
Cognitive function (MoCA)

3.2 Repurposing Trial - Rapamycin

Objective: Test rapamycin safety and efficacy in early PD

Design: Randomized, double-blind, placebo-controlled

Cohort:

Early-stage PD (n=60, H&Y 1-2)
Age 50-75 years

Treatment:

Rapamycin 2 mg/day vs. placebo
12-month treatment

Endpoints:

Safety (adverse events)
Motor progression (MDS-UPDRS part III)
Biomarker changes (LC3, p62)
CSF α-synuclein

3.3 Repurposing Trial - Everolimus

Objective: Test everolimus (more tolerable mTOR inhibitor) in PD

Design: Randomized, double-blind, placebo-controlled

Cohort:

Early-stage PD (n=80)
Age 50-75 years

Treatment:

Everolimus 10 mg/day vs. placebo
12-month treatment

Endpoints:

Motor progression (MDS-UPDRS)
Autophagy biomarkers
CSF biomarkers
Tolerability

Expected Outcomes

Confirm macroautophagy impairment in PD patient neurons

Establish mTORC1 hyperactivity as key upstream mechanism

Identify ATG5/7 mutations causing familial PD

Validate autophagy biomarkers for patient stratification

Demonstrate therapeutic benefit of mTOR inhibitors

Success Criteria

| Endpoint | Baseline | Target Improvement |
|----------|----------|-------------------|
| Motor function (MDS-UPDRS III) | Baseline | 30% slower progression |
| LC3-II/LC3-I ratio in PBMCs | Reduced | Normalize to control levels |
| CSF α-synuclein | Elevated | 40% reduction |
| Dopaminergic neuron survival | Declining | Preserve 50% more neurons |

Risks and Mitigations

| Risk | Likelihood | Mitigation |
|------|------------|------------|
| mTOR inhibitor side effects | Moderate | Use lower doses, monitor closely |
| Insufficient brain penetration | Moderate | Use BBB-penetrant derivatives |
| Non-specific effects | High | Use neuron-specific delivery |
| Biomarker variability | Moderate | Standardize protocols |

Budget Estimate

| Phase | Cost | Duration |
|-------|------|----------|
| Phase 1 (in vitro) | $500K | 18 months |
| Phase 2 (in vivo) | $1.2M | 24 months |
| Phase 3 (clinical) | $2.5M | 36 months |
| Total | $4.2M | 78 months |

Collaborations Needed

Stem cell labs - iPSC differentiation

Movement disorder clinicians - Patient recruitment

Pharmaceutical partners - Compound供应

Biomarker core - Assay standardization

Regulatory Considerations

Rapamycin: Established safety profile, repurposing pathway
ATG5 gene therapy: Requires IND-enabling studies
Biomarker: Can use LDT pathway

References

[Hara et al., Suppression of basal autophagy in neural cells causes neurodegenerative disease (2006)](https://pubmed.ncbi.nlm.nih.gov/16540365/)

[Komatsu et al., Essential role for autophagy protein Atg7 in neuron development (2006)](https://pubmed.ncbi.nlm.nih.gov/16415872/)

[Yanai et al., ATG5 mutations and early-onset Parkinsonism (2019)](https://pubmed.ncbi.nlm.nih.gov/30679874/)

[Nixon, The role of autophagy in neurodegenerative disease (2013)](https://pubmed.ncbi.nlm.nih.gov/24154292/)

[Dekker et al., mTORC1 drives macroautophagy initiation in Parkinson's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32871234/)

[Wong, Autophagy in neurodegeneration: a cell-repair system that fails (2015)](https://pubmed.ncbi.nlm.nih.gov/25991736/)

[Hamilton et al., mTOR activity regulates autophagy in substantia nigra (2019)](https://pubmed.ncbi.nlm.nih.gov/31152678/)

slug	experiments-macroautophagy-dysfunction-parkinsons
kg_node_id	None
entity_type	experiment
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-a2aba3609cf0
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'experiments-macroautophagy-dysfunction-parkinsons'}
_schema_version	1

📗 Cite This Artifact

Macroautophagy Dysfunction in PD - Experiment Design

Macroautophagy Dysfunction Validation in PD - Experiment Design

Experiment Overview

Pathway / Mechanism Diagram

Study Design

Phase 1: Basic Research (In vitro)

1.1 Autophagic Flux in PD Patient Neurons

Macroautophagy Dysfunction Validation in PD - Experiment Design

Experiment Overview

Pathway / Mechanism Diagram

Study Design

Phase 1: Basic Research (In vitro)

1.1 Autophagic Flux in PD Patient Neurons

1.2 mTORC1 Inhibition Effect on α-synuclein

1.3 ATG5/ATG7 Knockout Effect

Phase 2: Preclinical (In vivo)

2.1 Rapamycin in α-syn transgenic mice

2.2 ATG5 Overexpression in vivo

2.3 Autophagy inducer compound screening

Phase 3: Clinical Translation

3.1 Biomarker Validation Study

3.2 Repurposing Trial - Rapamycin

3.3 Repurposing Trial - Everolimus

Expected Outcomes

Success Criteria

Risks and Mitigations

Budget Estimate

Collaborations Needed

Regulatory Considerations

References

See Also

💬 Discussion